{"id":"at13387-and-imatinib","safety":{"commonSideEffects":[{"rate":"null","effect":"Myelosuppression"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"},{"rate":"null","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AT13387 works by selectively binding to the B-Raf V600E kinase, thereby inhibiting its activity and potentially leading to cancer cell death. Imatinib, on the other hand, targets multiple tyrosine kinases, including BCR-ABL, c-Kit, and PDGFR, which are involved in the proliferation and survival of cancer cells.","oneSentence":"AT13387 is a potent and selective inhibitor of the B-Raf V600E kinase, while Imatinib is a tyrosine kinase inhibitor targeting BCR-ABL, c-Kit, and PDGFR.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:43.967Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML), Acute lymphoblastic leukemia (ALL)"},{"name":"Gastrointestinal stromal tumors (GIST)"}]},"trialDetails":[{"nctId":"NCT01294202","phase":"PHASE2","title":"A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2011-03","conditions":"Gastrointestinal Stromal Tumor (GIST)","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gleevec"],"phase":"phase_2","status":"active","brandName":"AT13387 and Imatinib","genericName":"AT13387 and Imatinib","companyName":"Astex Pharmaceuticals, Inc.","companyId":"astex-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AT13387 is a potent and selective inhibitor of the B-Raf V600E kinase, while Imatinib is a tyrosine kinase inhibitor targeting BCR-ABL, c-Kit, and PDGFR. Used for Chronic myeloid leukemia (CML), Acute lymphoblastic leukemia (ALL), Gastrointestinal stromal tumors (GIST).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}